Sanofi to utilise Scribe's CRISPR platform to develop cancer cell therapies
FirstWord Pharma
|
September 27, 2022
X min read
FirstWord Pharma
|
September 27, 2022
Share on Social
More like this
Media
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
Press
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
